Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Update September 2024

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Update September 2024. Fact Sheet Nr. 163.

[thumbnail of Fact Sheet Nr.163_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
149kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:	English
Series Name:	Fact Sheet Nr. 163
Deposited on:	12 Feb 2024 17:37
Last Modified:	25 Sep 2024 14:43

Repository Staff Only: item control page